Cite

    Pieber, T. et al. (2022). Efficacy, safety, tolerability, and noninferiority phase 3 study of glucagon as a ready‐to‐use room temperature liquid stable formulation versus a lyophilised formulation for the biochemical recovery and symptomatic relief of insulin‐induced severe hypoglycaemia in adults with type 1 diabetes. Diabetes, obesity & metabolism. 24 (7), pp. 1394-1397. [Online].